Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy

Objective: To explore whether the frequencies and functional molecules expression of Natural Killer cells (NK cells) are related to hepatitis B surface antigen (HBsAg) disappearance in hepatitis B e envelope antigen (HBeAg)-positive patients with chronic hepatitis B (CHB) throughout peginterferon alpha-2a (PEG-IFN alpha-2a) treatment. Methods: In this prospective research, HBeAg-positive patients with CHB received PEG-IFN alpha-2a treatment, completing 4-year follow-up. After PEG-IFN alpha-2a treatment, undetectable HBV DNA, HBsAg loss, and HBeAg disappearance were defined as functional cure. Proportions of NK, CD56(dim), CD56(bright), NKp46(+), NKp46(dim), NKp46(high), and interferon alpha receptor 2 (IFNAR2)(+) NK cells, and the mean fluorescence intensity (MFI) of NK cell surface receptors IFNAR2 and NKp46 were detected. Results: 66 patients were enrolled into the study in which 17 patients obtained functional cure. At baseline, hepatitis B virus desoxyribose nucleic acid (HBV DNA) titer in patients with functional cure was remarkably lower than that in Non-functional cure group. Compared with baseline, HBV DNA levels, HBsAg levels, and HBeAg levels significantly declined at week 12 and 24 of therapy in patients with functional cure. At baseline, the negative correlation between CD56(bright) NK% and HBV DNA and the negative correlation between CD56(dim) NK% and HBV DNA was showed; CD56(bright) NK% and IFNAR2 MFI in patients with functional cure were remarkably higher than those in patients without functional cure. After therapy, CD56(bright) NK% and NKp46(high) NK% in patients with functional cure were higher than those in patients without functional cure. In Functional cure group, after 24 weeks of treatment NK%, CD56(bright) NK%, IFNAR2 MFI weakly increased, and NKp46(high) NK% and NKp46 MFI significantly increased, meanwhile, CD56(dim) NK% and NKp46(dim) NK% decreased. Only NKp46 MFI increased after therapy in patients without functional cure. Conclusion: The lower HBV DNA load and the higher CD56(bright) NK% before therapy, and the higher the post-treatment CD56(bright) NK%, IFNAR2 MFI, NKp46(high) NK%, the easier to achieve functional cure.

Automated summary

The study found that CHB patients with lower HBV DNA load and higher CD56(bright) NK% before treatment were more likely to achieve functional cure. After treatment, an increase in CD56(bright) NK%, IFNAR2 MFI, and NKp46(high) NK% was associated with a higher chance of functional cure.